ProCE Banner Activity

RELATIVITY-047: Phase II/III Trial of First-line Relatlimab + Nivolumab vs Nivolumab Alone in Advanced Melanoma

Slideset Download
Conference Coverage
Dual LAG-3 and PD-1 inhibition with a fixed-dose combination of relatlimab + nivolumab demonstrated superior PFS compared with nivolumab alone in patients with advanced melanoma.

Released: June 07, 2021

Expiration: June 06, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme